首页|AAV for Gene Therapy in Ocular Diseases:Progress and Prospects

AAV for Gene Therapy in Ocular Diseases:Progress and Prospects

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Owing to the promising therapeutic effect and one-time treatment advantage,gene therapy may completely change the management of eye diseases,especially retinal diseases.Adeno-associated virus(AAV)is considered one of the most promising viral gene delivery tools because it can infect various types of tissues and is considered as a relatively safe gene delivery vector.The eye is one of the most popular organs for gene therapy,since its limited volume is suitable for small doses of AAV stably transduction.Recently,an increasing number of clinical trials of AAV-mediated gene therapy are underway.This review summarizes the biological functions of AAV and its application in the treatment of various ocular diseases,as well as the characteristics of different AAV delivery routes in clinical applications.Here,the latest research progresses in AAV-mediated gene editing and silencing strategies to modify that the genetic ocular diseases are systematically outlined,especially by base editing and prime editing.We discuss the progress of AAV in ocular optogenetic therapy.We also summarize the application of AAV-mediated gene therapy in animal models and the difficulties in its clinical transformation.

Xiaoyu He、Yidian Fu、Liang Ma、Yizheng Yao、Shengfang Ge、Zhi Yang、Xianqun Fan

展开 >

Department of Ophthalmology,Ninth People's Hospital,Shanghai JiaoTong University School of Medicine,Shanghai,China

Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology,Shanghai,China

Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience,Soochow University

2024

10.34133/research.0291

研究(英文)

研究(英文)

CSTPCD
ISSN：
年,卷(期)：2024.2024(3)